1. Executive Summary
1. Market Overview
1. Market Landscape
1. Market ecosystem
2. Value chain analysis
1. Market Sizing
1. Market definition
2. Market segment analysis
3. Market size 2019
4. Market outlook: Forecast for 2019 – 2024
1. Five Forces Analysis
1. Five Forces Summary
2. Bargaining power of buyers
3. Bargaining power of suppliers
4. Threat of new entrants
5. Threat of substitutes
6. Threat of rivalry
7. Market condition
1. Market Segmentation by Product
1. Market segments
2. Comparison by Product placement
3. Antidepressants – Market size and forecast 2019-2024
4. Anxiolytics – Market size and forecast 2019-2024
5. Other PTSD therapeutics – Market size and forecast 2019-2024
6. Market opportunity by Product
1. Customer landscape
1. Overview
1. Geographic Landscape
1. Geographic segmentation
2. Geographic comparison
3. North America – Market size and forecast 2019-2024
4. APAC – Market size and forecast 2019-2024
5. Europe – Market size and forecast 2019-2024
6. South America – Market size and forecast 2019-2024
7. MEA – Market size and forecast 2019-2024
8. Key leading countries
9. Market opportunity by geography
1. Drivers, Challenges, and Trends
1. Market drivers
2. Volume driver – Demand led growth
3. Volume driver – Supply led growth
4. Volume driver – External factors
5. Volume driver – Demand shift in adjacent markets
6. Price driver – Inflation
7. Price driver – Shift from lower to higher priced units
8. Market challenges
9. Market trends
1. Vendor Landscape
1. Overview
2. Vendor landscape
3. Landscape disruption
1. Vendor Analysis
1. Vendors covered
2. Market positioning of vendors
3. AstraZeneca Plc
4. Azevan Pharmaceuticals Inc.
5. Bionomics Ltd.
6. Eli Lilly and Co.
7. GlaxoSmithKline Plc
8. H. Lundbeck AS
9. Mylan NV
10. Neurocrine Biosciences Inc.
11. Novartis International AG
12. Pfizer Inc.
1. Appendix
1. Scope of the report
2. Currency conversion rates for US$
3. Research methodology
4. List of abbreviations
Exhibits
1.Key Finding 1
2.Key Finding 2
3.Key Finding 3
4.Key Finding 4
5.Key Finding 5
6.Key Finding 6
7.Key Finding 7
8.Market in focus
9.Parent market
10.Market characteristics
11.Product / Service portfolio of key vendors included in the market definition
12.Market segments
13.Global – Market size and forecast 2019 – 2024 ($ million)
14.Global market: Year-over-year growth 2019 – 2024 (%)
15.Five forces analysis 2019 & 2024
16.Bargaining power of buyers
17.Bargaining power of suppliers
18.Threat of new entrants
19.Threat of substitutes
20.Threat of rivalry
21.Market condition – Five forces 2019
22.Product placement – Market share 2019-2024 (%)
23.Comparison by Product placement
24.Antidepressants – Market size and forecast 2019-2024 ($ million)
25.Antidepressants – Year-over-year growth 2019-2024 (%)
26.Anxiolytics – Market size and forecast 2019-2024 ($ million)
27.Anxiolytics – Year-over-year growth 2019-2024 (%)
28.Other PTSD therapeutics – Market size and forecast 2019-2024 ($ million)
29.Other PTSD therapeutics – Year-over-year growth 2019-2024 (%)
30. Market opportunity by Product
31.Customer landscape
32.Market share by geography 2019-2024 (%)
33.Geographic comparison
34.North America – Market size and forecast 2019-2024 ($ million)
35.North America – Year-over-year growth 2019-2024 (%)
36.APAC – Market size and forecast 2019-2024 ($ million)
37.APAC – Year-over-year growth 2019-2024 (%)
38.Europe – Market size and forecast 2019-2024 ($ million)
39.Europe – Year-over-year growth 2019-2024 (%)
40.South America – Market size and forecast 2019-2024 ($ million)
41.South America – Year-over-year growth 2019-2024 (%)
42.MEA – Market size and forecast 2019-2024 ($ million)
43.MEA – Year-over-year growth 2019-2024 (%)
44.Key leading countries
45.Market opportunity by geography ($ million)
46.Impact of drivers
47.Impact of challenges
48.Landscape disruption
49.Industry risks
50.Vendors covered
51.Market positioning of vendors
52.AstraZeneca Plc – Overview (1/3)
53.AstraZeneca Plc – Overview (2/3)
54.AstraZeneca Plc – Overview (3/3)
55.AstraZeneca Plc – Product and service
56.AstraZeneca Plc – Key offerings
57.AstraZeneca Plc – Key customers
58.AstraZeneca Plc – Segment focus
59.Azevan Pharmaceuticals Inc. – Overview (1/3)
60.Azevan Pharmaceuticals Inc. – Overview (2/3)
61.Azevan Pharmaceuticals Inc. – Overview (3/3)
62.Azevan Pharmaceuticals Inc. – Product and service
63.Azevan Pharmaceuticals Inc. – Key offerings
64.Azevan Pharmaceuticals Inc. – Key customers
65.Azevan Pharmaceuticals Inc. – Segment focus
66.Bionomics Ltd. – Overview (1/3)
67.Bionomics Ltd. – Overview (2/3)
68.Bionomics Ltd. – Overview (3/3)
69.Bionomics Ltd. – Business segments
70.Bionomics Ltd. – Key offerings
71.Bionomics Ltd. – Key customers
72.Bionomics Ltd. – Segment focus
73.Eli Lilly and Co. – Overview (1/3)
74.Eli Lilly and Co. – Overview (2/3)
75.Eli Lilly and Co. – Overview (3/3)
76.Eli Lilly and Co. – Business segments
77.Eli Lilly and Co. – Key offerings
78.Eli Lilly and Co. – Key customers
79.Eli Lilly and Co. – Segment focus
80.GlaxoSmithKline Plc – Overview (1/3)
81.GlaxoSmithKline Plc – Overview (2/3)
82.GlaxoSmithKline Plc – Overview (3/3)
83.GlaxoSmithKline Plc – Business segments
84.GlaxoSmithKline Plc – Key offerings
85.GlaxoSmithKline Plc – Key customers
86.GlaxoSmithKline Plc – Segment focus
87.H. Lundbeck AS – Overview (1/3)
88.H. Lundbeck AS – Overview (2/3)
89.H. Lundbeck AS – Overview (3/3)
90.H. Lundbeck AS – Product and service
91.H. Lundbeck AS – Key offerings
92.H. Lundbeck AS – Key customers
93.H. Lundbeck AS – Segment focus
94.Mylan NV – Overview (1/3)
95.Mylan NV – Overview (2/3)
96.Mylan NV – Overview (3/3)
97.Mylan NV – Business segments
98.Mylan NV – Key offerings
99.Mylan NV – Key customers
100.Mylan NV – Segment focus
101.Neurocrine Biosciences Inc. – Overview (1/3)
102.Neurocrine Biosciences Inc. – Overview (2/3)
103.Neurocrine Biosciences Inc. – Overview (3/3)
104.Neurocrine Biosciences Inc. – Business segments
105.Neurocrine Biosciences Inc. – Key offerings
106.Neurocrine Biosciences Inc. – Key customers
107.Neurocrine Biosciences Inc. – Segment focus
108.Novartis International AG – Overview (1/3)
109.Novartis International AG – Overview (2/3)
110.Novartis International AG – Overview (3/3)
111.Novartis International AG – Business segments
112.Novartis International AG – Key offerings
113.Novartis International AG – Key customers
114.Novartis International AG – Segment focus
115.Pfizer Inc. – Overview (1/3)
116.Pfizer Inc. – Overview (2/3)
117.Pfizer Inc. – Overview (3/3)
118.Pfizer Inc. – Business segments
119.Pfizer Inc. – Key offerings
120.Pfizer Inc. – Key customers
121.Pfizer Inc. – Segment focus
122.Currency conversion rates for US$
123.Research Methodology
124.Validation techniques employed for market sizing
125.Information sources
126.List of abbreviations
